Xeris Biopharma (NASDAQ:XERS) Director John Johnson Sells 15,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson sold 15,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $91,350.00. Following the completion of the sale, the director directly owned 683,083 shares of the company’s stock, valued at approximately $4,159,975.47. This represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Up 0.5%

Shares of Xeris Biopharma stock opened at $6.18 on Friday. The stock has a 50-day moving average price of $6.10 and a 200 day moving average price of $6.59. The company has a market cap of $1.07 billion, a P/E ratio of 103.00 and a beta of 0.78. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a 1 year low of $4.30 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on XERS. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research note on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.80.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in XERS. Royal Bank of Canada increased its holdings in shares of Xeris Biopharma by 1,411.2% during the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after acquiring an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after acquiring an additional 3,594 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after acquiring an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP acquired a new position in shares of Xeris Biopharma during the 1st quarter valued at about $170,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.